|
BACKGROUND
Glioblastoma (GBM) is the most common and aggressive brain cancer, and accounts for 60% of adult brain tumours. The median survival of adult GBM patients is 15 months, where the standard-of-care is a combination of surgery, radiation, and chemotherapy using the DNA alkylating agent temozolomide (TMZ), which extends patient survival by...
|
